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Zymogen activationThe gelatinases, matrix metalloproteinase (MMP)-9 and -2, are produced as latent, inactive enzymes that can
be proteolytically activated by a number of proteases. In many normal and pathological conditions, where the
expression of MMPs is deregulated, changes in the expression of other proteases have also been reported.
Human kallikrein-related peptidase 7 (KLK7), a chymotryptic-like serine protease, is overexpressed in many
different types of neoplastic conditions, which have also been shown to express high levels of both MMP-9
and -2. Since the activation of MMPs by KLK7 has never been examined, we sought to determine whether
KLK7 can activate these MMPs. To test this hypothesis KLK7 was incubated with the recombinant MMPs and
the products of the reaction were analyzed for their activity. Incubation of proMMP-9 with KLK7 resulted in
the production of a novel truncated, active MMP-9 lacking the C-terminal hemopexin domains. In contrast,
KLK7 degraded, but did not activate, proMMP-2. The novel activation of proMMP-9 by KLK7 was further
conﬁrmed using conditioned medium prepared from an MMP-9-expressing cell line, MDA-MMP-9. Our
results clearly establish that KLK7 activates proMMP-9 to produce a novel truncated, active MMP-9 product
not generated by other proteases. These ﬁndings suggest that KLK7 may play an important role in the
activation of MMP-9 in tumors that express high levels of both these proteases and the resulting truncated
MMP may possess altered substrate speciﬁcities compared with full-length MMP-9 activated by other
proteases.3, Little Rock, AR 72205, USA.
HaunRandyS@uams.edu
ersity of Alabama School of
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Matrix metalloproteinases (MMPs) comprise a family of zinc-
dependent, neutral endopeptidases that participate in the degrada-
tion of the extracellular matrix and remodeling in both normal and
pathological conditions, including cancer. During metastasis, tumor
cells must detach from the primary tumor, migrate, and invade
surrounding tissues—processes that are actively facilitated by MMPs.
Members of the MMP family have been studied in detail for their
ability to inﬂuence the progression of different types of cancers [1–3];
and various MMPs have been shown to regulate tumor progression by
proteolysis of extracellular matrix proteins [4], remodeling the tumor
microenvironment [5], processing cell–cell adhesion molecules [6],
selecting tumor cells resistant to apoptosis [7], and promoting tumorangiogenesis [8]. In particular, degradation of the basement mem-
brane, comprised predominately of type IV collagen, is carried out by
the gelatinases (MMP-2 and MMP-9).
MMPs are secreted as latent, inactive proenzymes that can be
converted into active enzymes by proteolytic removal of the
propeptide domain containing a highly conserved cysteine residue
that forms an intramolecular complex with the active site zinc atom
[9,10]. Many extracellular proteases have been demonstrated to
directly activate MMPs including other MMPs (e.g., MMP-3 activation
of the MMP-9 [11]) and non-MMP proteins (e.g., plasmin activation of
MMP-3 [12]). High levels of metalloproteinases, especially MMP-2
and/or MMP-9 have been demonstrated in many cancers, including
pancreatic [13–20], breast [21], cervical [22], and ovarian cancer [23].
Similarly, the human kallikrein-related peptidases constitute an
important group of serine proteases that are up-regulated in various
cancers (reviewed in [24,25]). In particular, kallikrein-related pepti-
dase 7 (KLK7) has also been reported to be overexpressed in human
pancreatic [26], breast [27], cervical [28], and ovarian cancer [29–31].
Dysregulated KLK expression in neoplastic tissues may play a role in
tumor growth, invasion, metastasis, and angiogenesis (reviewed in
[24,32,33]). The co-expression of KLK7 and MMP-2 and -9 prompted
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from our experiments clearly show that KLK7 can activate puriﬁed
proMMP-9, but not proMMP-2, in vitro to produce a novel active
MMP-9 gelatinolytic fragment that lacks the C-terminal hemopexin
domains, which is in contrast to the 83-kDa product produced by
other proteases. Kallikrein-related peptidase 7 was also able to
activate proMMP-9 secreted in conditioned medium by MDA-MMP-
9 cells in a similar fashion. These results highlight a novel role for KLK7
in the activation of MMP-9 in tissues where both these proteases are
highly expressed and should temper the assignment of gelatinolytic
activity based solely on gel mobility in mixtures of MMPs. Importantly
such activation of MMP-9 by KLK7 in pathological conditions, like
cancer, could result in truncated MMP-9 that may exhibit altered
substrate speciﬁcity and not be targeted by current therapies.
2. Materials and methods
2.1. Cell culture and conditioned media
MDA-MMP-9 cells (kindly provided by Dr. James P. Quigley) and
the parental breast cancer cell line MDA-MB-231 were seeded in 10-
cm dishes and grown to 70% conﬂuence in Dulbecco'sModiﬁed Eagle's
Medium (Invitrogen, Carlsbad, CA) containing 10% fetal bovine serum
(Atlanta Biologicals, Norcross, GA) at 37 °C in a 5% CO2/air environ-
ment. Geneticin (600 μg/ml) was included in the culture medium for
the MDA-MMP-9 cells. For preparation of conditioned media, growth
media was removed, cells were washed twice in phosphate-buffered
saline, and incubated in serum-free medium (SFM) for 48 h. After
incubation, the conditioned media was removed, centrifuged at
1500 rpm at 4 °C to remove any cell debris, aliquoted, and stored at
−20 °C.
2.2. Activation of proKLK7
Recombinant, proKLK7 (100 μg/mL) (R&D Systems, Minneapolis,
MN) was proteolytically activated using thermolysin as described
previously [34]. To activate with plasmin, equal molar amounts of
proKLK7 and plasmin (EMD Chemicals) were incubated at 37 °C for
4 h in 50 mM Tris–HCl, pH 7.2, 0.15 M NaCl. Plasmin activity was
terminated by addition of D-Val-Phe-Lys chloromethyl ketone (VFK-
CK, EMD Chemicals), a selective irreversible plasmin inhibitor.
2.3. Gelatin zymography
For gelatin zymography, mixtures after incubation were mixed
with non-reducing SDS-PAGE sample buffer and incubated at RT for
10 min. The samples were then resolved in 15% or 20% acrylamide
SDS-PAGE gels containing 10 mg/ml of porcine gelatin. After electro-
phoresis, the gels were washed for 1 h in renaturing buffer (2.5%
Triton X-100) and incubated overnight in developing buffer (50 mM
Tris, pH 7.5, 200 mM NaCl, and 5 mM CaCl2) at 37 °C with constant
shaking. The gels were then stainedwith 0.1% Coomassie Brilliant Blue
R-250 (Bio-Rad Laboratories, Richmond, CA) in 50%methanol and 10%
acetic acid overnight. The bands were visualized after repeated
washes with a 50% methanol, 10% acetic acid solution.
2.4. Activation of proMMP-9 and proMMP-2 by KLK7
ProMMP-9 and proMMP-2 (1 pmol) (EMD Biosciences, La Jolla,
CA) were incubated with 0.2 pmol of thermolysin-activated KLK7 at
37 °C in KLK7 activity buffer (50 mM Tris–HCl, pH 8.5, 0.15 M NaCl)
containing 50 mM EDTA (to inhibit thermolysin). At various time
intervals samples were removed and resolved on 4–12% Bis-Tris
polyacrylamide gels (Invitrogen) for western blots or 20% polyacryl-
amide gels containing 0.1% gelatin to monitor gelatinolytic activity. As
controls, proMMP-9 or proMMP-2 alone or with 1 ng of thermolysin,were incubated under similar conditions separately for 4 h. As a
further control, thermolysin-activated KLK7 was incubated in the
presence of 50 mM EDTA for 4 h.2.5. Activation of proMMP-9 by KLK7 in conditioned medium of
MDA-MMP-9 cells
Conditioned media (20 μl) from MDA-MMP-9 cells was incubated
with 100 ng of thermolysin-activated KLK7 in the presence of 50 mM
EDTA at 37 °C for 0, 30, 60, 120, 240 minutes. At each time point, an
aliquot was removed for gelatin zymography. As controls, 20 μl of
MDA-MMP-9 conditionedmediawas incubated alone or with 10 ng of
thermolysin in presence of 50 mM EDTA at 37 °C for 4 h. As a positive
control, 1 pmol of recombinant proMMP-9 was incubated with
0.2 pmol of thermolysin-activated KLK7 in 20 μl of SFM containing
50 mM EDTA for 4 h at 37 °C.2.6. Activation of recombinant proMMP-9 by KLK7 in MDA-MB-231
conditioned media
ProMMP-9 (1 pmol) was incubated with 0.2 pmol of thermolysin-
activated KLK7 in 20 μl of MDA-MB-231 conditioned media in the
presence of 50 mM EDTA at 37 °C. As controls, 20 μl of conditioned
media was incubated alone, with 100 ng proMMP-9, or with 100 ng
proMMP-9 and 1 ng thermolysin at 37 °C in the presence of 50 mM
EDTA.As apositive control, proMMP-9was incubatedwith thermolysin-
activated KLK7 in 20 μl of SFM containing 50 mM EDTA at 37 °C. After
4 h, the samples were analyzed by gelatin zymography, visualized by
Coomassie Blue staining, and the sizes of the novel gelatinolytic
fragments were determined using an AlphaEase image documentation
system and analysis software (Alpha Innotech, San Leandro, CA).2.7. Activation of proMMP-9 by KLK7 in TIMP-1-immunodepleted
conditioned medium of MDA-MB-231 cells
MDA-MB-231 conditioned medium (500 μl) was incubated with
2 μg of anti-TIMP-1 antibody (R&D Systems) on a rotating mixer
overnight at 4 °C. As a control, 500 μl of conditioned medium was
incubated with 2 μg of normal goat IgG antibody (R&D Systems)
under similar conditions. Immunocomplexes were removed by
addition of a 50% slurry of protein G Sepharose 4 Fast Flow (GE
Healthcare, Piscataway, NJ), mixing for 2 h at 4 °C, followed by
centrifugation. ProMMP-9 (1 pmol) was incubated with 0.2 pmol
thermolysin-activated KLK7 in 20 μl of TIMP-1-immunodepleted
MDA-MB-231 conditioned medium or control IgG-treated condi-
tioned medium in the presence of 50 mM EDTA for 4 h at 37 °C. As
controls, 20 μl of TIMP-1 or control immunodepleted conditioned
medium was incubated alone, with 1 pmol of proMMP-9, or with 1
pmol of proMMP-9 and 1 ng thermolysin in presence of 50 mM EDTA
for 4 h at 37 °C. As a positive control, 1 pmol of proMMP-9 was
incubated with 0.2 pmol thermolysin-activated KLK7 in 20 μl of SFM
containing 50 mM EDTA for 4 h at 37 °C. At the end of incubation, one
aliquot was subjected to gelatin zymography and a second aliquot was
analyzed by western blot for the presence of TIMP-1.2.8. Western blot analysis of KLK7-cleaved proMMP-9
For detection of proMMP-9 products cleaved by KLK7 using
western blot analysis, PVDF membranes were incubated with MMP-9
antibodies generated using full-length proMMP-9 (AF911, R&D
Systems), the catalytic domain of MMP-9 (AB19016, Millipore), or
peptide immunogens located in the C-terminus of MMP-9 (M5177,
Sigma-Aldrich; 56-2A4, Millipore).
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To determine the KLK7 cleavage site of MMP-9, 50 pmol of
proMMP-9 was incubated with 10 pmol of thermolysin-activated
KLK7 for 4 h at 37 °C. The reaction was terminated by heating at 95 °C
for 5 minutes following the addition of SDS-PAGE sample buffer. The
products were resolved on a 14% acrylamide/SDS gel, transferred to
PVDF membrane, and visualized with 0.2% Ponceau-S stain in 1%
acetic acid. Themembrane with truncated ~48-kDa band was excised,
washed in methanol followed by distilled water, and submitted to the
Harvard Microchemistry Facility for protein sequence analysis.
3. Results
Since MMPs-2 and -9 and KLK7 have been observed to be
overexpressed in various cancers, we examined the ability of KLK7
to activate these MMPs. Upon incubation, recombinant proMMP-9
was cleaved by KLK7 in a time-dependent manner giving rise to a
distinct truncated, proteolytically active product as visualized by
gelatin zymography (Fig. 1A). By 4 h, the full-length 92-kDa proMMP-
9 was almost entirely cleaved by KLK7 resulting in a low molecular
weight gelatinase activity (Fig. 1A, arrowhead labeled tMMP-9). To
conﬁrm that the gelatinolytic activity resulted from MMP-9 activated
by KLK7 and not by the thermolysin used to activate KLK7, proMMP-9
was incubated without and with thermolysin in the presence of EDTA
(Fig. 1A, lanes 7 and 8, respectively). Although thermolysin exhibited
signiﬁcant gelatinase activity (Fig. 1A, arrow labeled therm), it did notFig. 1. ProMMP-9 but not proMMP-2 is activated by KLK7. (A) Recombinant proMMP-9
(1 pmol) or (B) proMMP-2 was incubated with 0.2 pmol of thermolysin-activated KLK7
at 37 °C for the indicated times (lanes 1–6) in activity buffer containing 50 mM EDTA
and the products were separated by SDS-PAGE and visualized by gelatin zymography.
As controls, 1 pmol of the corresponding proMMP was incubated without (lane 7) or
with thermolysin (lane 8) in the presence of EDTA (to inhibit thermolysin activity) for
4 h, or 0.2 pmol of thermolysin-activated KLK7 was incubated for 4 h (lane 9) prior to
gel analysis. The predominant proteolytically active truncated MMP-9 (tMMP-9)
fragment produced by KLK7 is denoted with arrowheads and gelatinolytic activity
corresponding to thermolysin (therm) is indicated by the arrows. Sizes of the protein
markers (kDa) are indicated on the left.produce the truncated, active MMP-9 band observed in the presence
of KLK7. Similarly, gelatin zymography of thermolysin-activated KLK7
only elicited gelatinolytic activity from the thermolysin and not KLK7
(Fig. 1A, lane 9). To inhibit thermolysin activity, EDTA was included in
the reactions during the incubation period; however, thermolysin
activity was restored following electrophoresis as indicated by its
robust gelatinolytic activity in the control reactions. To rule out the
possibility that EDTA in the reactions could have inﬂuenced the
conformation of MMP-9 leading to this unique activation with KLK7,
we tested MMP-9 activation using plasmin-activated KLK7. Gelatin
zymography of the reaction products revealed that a similar
truncated, gelatinolytically-active MMP-9 fragment was produced
with either plasmin-activated KLK7 or thermolysin-activated KLK7
(data not shown); thus, eliminating the notion that EDTA inﬂuences
the activation of proMMP-9 by KLK7. In contrast to the activation of
MMP-9 by KLK7, incubation of proMMP-2 with KLK7 resulted in a
time-dependent degradation of MMP-2 gelatinase activity without
yielding any distinct major gelatinolytic fragments (Fig. 1B). Thus,
among these MMPs, activation by KLK7 appears to be speciﬁc for
MMP-9.
To determine the site of cleavage by KLK7 to produce the truncated
MMP-9, proMMP-9was incubatedwith KLK7 and the reaction products
were loaded in two lanes of a 14% SDS-PAGE gel. Following
electrophoresis, the two lanes were divided and one was stained with
Coomassie Blue to visualize the reaction products (Fig. 2) while the
other was transferred to PVDF membrane and stained with Ponceau S.
Themajor band observed, corresponding to the truncatedMMP-9 band
detected by Coomassie Blue (Fig. 2, arrowhead labeled tMMP-9), was
excised and submitted for N-terminal sequence analysis. Five cycles of
Edmandegradation performed on theKLK7-cleavedMMP-9 yielded the
sequence(s) T/[G]-P-R-P-E (amino acid in brackets reported with
reasonable conﬁdence). The N-terminal sequence G-P-R-P-E was
veriﬁed in a second preparation, however, no sequence data were ob-
tained for the 51-kDa catalytic domain in either preparation, presum-
ably because its N-terminus is blocked. Inspection of the proMMP-9Fig. 2. N-terminal sequence analysis. Recombinant proMMP-9 was incubated with
activated KLK7 and the reaction products were fractionated on a 14% Tris-glycine gel.
Following electrophoresis the gel was divided and the reaction products in one portion
were visualized by Coomassie Blue stain. Sizes of the protein markers (kDa) are
indicated on the left. The other gel portion was transferred to PVDF membrane, stained
with Ponceau S and the membrane containing the major truncated MMP-9 (tMMP-9)
product (corresponding to the band visualized by Coomassie Blue) was excised and
submitted for N-terminal sequence analysis yielding the sequence GPRPE.
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located between the consensus HEFGHALGLDH catalytic domain motif
and hemopexin-like domains (HP) in the C-terminus. This sequence is
preceded by a tyrosine residue, the most favored P1 residue of KLK7 as
determined by substrate speciﬁcity proﬁling [35], supporting the notion
that this represents a KLK7 cleavage site.
It is also noteworthy that catalytically active recombinant forms of
MMP-9 have been produced that were truncated following the
protease domain at almost the same site (GPRPE) cleaved by KLK7
[36,37]. Intriguingly, the mobility of the catalytically active portion of
MMP-9 produced by KLK7 identiﬁed by gelatin zymography is very
similar to that observed for truncated murine MMP-9 [36].
To further characterize the MMP-9 cleavage products produced by
KLK7, proMMP-9 was incubated with KLK7 and the reaction products
were loaded in multiple lanes of 4–12% Bis-Tris gels. Following transfer
toPVDFmembranes the cleavageof proMMP-9byKLK7wasassessed by
western blot analysis using various MMP-9 antibodies (Fig. 3B). Using
an antibody (AF911, R&D Systems) generated against recombinant
proMMP-9, twoproteolytic productsweredetected corresponding to51
and 48 kDa. Immunoblots incubated with an antibody targeting the
catalytic domain of MMP-9 (AB19016, Millipore) revealed that the 51-
kDa band represents the novel truncatedMMP-9 fragment observed by
gelatin zymography (Fig. 1A, arrowhead labeled tMMP-9). Consistent
with this ﬁnding, antibodies produced using peptide immunogens
derived from the C-terminus of MMP-9 detected the 48-kDa band,
which represents the C-terminal portion of MMP-9 containing the
hemopexin domains. This C-terminal fragment would be produced by
cleavage between Tyr443 and Gly444 yielding the N-terminal sequence
GPRPE that was identiﬁed by Edman sequencing. Due to their similar
size, the 51- and 48-kDaMMP-9 fragments were only resolved using 4–
12% gradient Bis-Tris gels (Fig. 3B) and not when the reaction products
were fractionated using a 14% Tris-glycine gel (Fig. 2).
To determine whether KLK7 can activate proMMP-9 in the context
of other secreted cellular products, conditioned medium was
prepared from MDA-MMP-9 cells, which are MDA-MB-231 cells,
derived from a breast carcinoma, transfected to express high levels of
MMP-9 [11], but do not express KLK7 [38]. Upon incubation with
KLK7, proMMP-9 in the conditioned medium was efﬁciently cleavedFig. 3. Western blot analysis of proMMP-9 cleavage products. (A) Schematic diagram of
(HEFGHALGLDH), and hemopexin (HP) domains. The MMP-9 immunogens used to generat
(B) Recombinant proMMP-9 was incubated with activated KLK7 for the indicated times and
electrophoresis, the products were transferred to PVDF membranes and detected with the in
to determine the size of the MMP-9 products. Sizes of the protein markers (kDa) are indicaby KLK7 to yield a 51-kDa truncated gelatinolytic fragment (Fig. 4,
arrowhead), which is similar to that observed with puriﬁed,
recombinant MMP-9 (Fig. 1A). Interestingly, an additional gelatino-
lytically-active MMP-9 band was also seen in experiments using the
MDA-MMP-9 conditioned medium. Both fragments were also pro-
duced in a control reaction when recombinant proMMP-9 was
incubated with KLK7 in SFM rather than KLK7 activity buffer (Fig. 4,
lane 8, arrowheads), suggesting that an additional site within MMP-9
becomes susceptible to cleavage by KLK7 in these buffer conditions.
Neither the conditioned medium alone nor conditioned mediumwith
thermolysin produced these active MMP-9 products (Fig. 4, lanes 6
and 7, respectively).
To identify soluble factors in conditioned media that may regulate
KLK7-mediated activation of MMP-9, MDA-MB-231 cells were
employed for further in vitro activation studies. MDA-MD-231 cells,
the parental cells transfected to produce high levels of MMP-9, did not
exhibit detectable levels of MMP-9 as measured by gelatin zymo-
graphy (Fig. 5A, lane 1). These cells should possess the same cellular
factors regulating activation of MMP-9 as the MDA-MMP-9 cells and
thus provide a context for manipulating the exogenous levels of both
KLK7 and MMP-9. Interestingly, in the presence of MDA-MB-231
conditionedmediumKLK7 did not activate recombinant proMMP-9 in
a fashion similar to that observed with SFM (Fig. 5A, compare lanes 4
and 5). Incubation with active KLK7 produced only low levels of a
~51-kDa fragment (Fig. 5A, lane 4). These results indicate that there is
a factor in the conditioned medium that regulates KLK7 activation of
proMMP-9.
One of the secreted factors that has been studied extensively in
regulating the activation, as well as activity, of MMPs is TIMP-1 (tissue
inhibitor ofmetalloproteinase-1) [39]. To test the role of TIMP-1 in KLK7-
mediated activation of proMMP-9, proMMP-9 was incubated with KLK7
in MDA-MB-231 conditioned medium with (Fig. 5B) and without
(Fig. 5C) immunodepletion of TIMP-1. Immunodepletion of TIMP-1
from MDA-MB-231 conditioned medium resulted in the formation of
both truncated MMP-9 products (Fig. 5B, lane 4, arrowheads), similar to
the gelatinolytic bands produced with SFM (Fig. 5B, lane 5). Parallel
reactions performed with MDA-MB-231 conditioned medium immuno-
depletedwith normal goat IgG exhibited almost complete attenuation ofpreproMMP-9 depicting the locations of the ﬁbronectin (FN), zinc-binding catalytic
e the MMP-9 antibodies used for western analysis are indicated by the horizontal lines
the reaction products were loaded in multiple lanes of 4–12% Bis-Tris gels. Following
dicated MMP-9 antibodies. MagicMarkXP (Invitrogen) protein standards (M) were used
ted on the right.
Fig. 4. KLK7 activates proMMP-9 secreted by MDA-MMP-9 cells. Conditioned medium
from MDA-MMP-9 cells was incubated at 37 °C with 100 ng of thermolysin-activated
KLK7 in the presence of 50 mM EDTA for the indicated times (lanes 1–5). As controls,
conditioned medium was incubated without (lane 6) or with thermolysin (lane 7)
under similar conditions for 4 h. As a positive control, 1 pmol of proMMP-9 was
incubated with 0.2 pmol thermolysin-activated KLK7 (lane 8) in SFM containing EDTA
for 4 hrs. At the end of the incubation period the products were analyzed by gelatin
zymography. The truncatedMMP-9 (tMMP-9) gelatinolytic products produced by KLK7
are denoted by the arrowheads and thermolysin-directed proteolysis (therm) is
indicated by the arrow. Sizes of the protein markers (kDa) are indicated on the left.
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The removal of TIMP-1 from the conditioned medium (Fig. 5B, lower
panel) and its retention with control immunoglobulins (Fig. 5C, lower
panel) was veriﬁed by western blot. These results clearly show that
TIMP-1 can regulate KLK7-mediated cleavage of MMP-9.4. Discussion
Matrixmetalloproteinases play a key role in the progression ofmany
disease conditions including cancer. The members of this family—
including the collagenases, stromelysins, gelatinases, and membrane-
type metalloproteases—are zinc-containing, neutral endopeptidases,
comprised of multiple domains that are characterized by their ability to
degrade various extracellular proteins. Both the expression and the
activity of MMPs are regulated and controlled at different levels [40].
Matrix metalloproteinases, like MMP-9, have been found to be
expressed by various normal cell types and also by certain cancer cells
[41–43]. Previous studies have shown that MMP-9 is a key player
in physiological processes in both normal and disease conditions.Fig. 5. TIMP-1 inMDA-MB-231 conditionedmedium regulates KLK7 activation of proMMP-9.
for 4 h with no additions (lane 1), with 1 pmol proMMP-9 (lane 2), with 1 pmol proMMP-9 a
KLK7 (lane 4). As a positive control, 1 pmol proMMP-9 was incubated with 0.2 pmol thermo
incubation period, the samples were analyzed by gelatin zymography. MDA-MB-231 conditi
The immunodepleted conditioned mediumwas incubated with the additions indicated in (A
for TIMP-1 (lower panels). As a positive control, 1 pmol proMMP-9 was incubated with 0.2
truncated MMP-9 (tMMP-9) gelatinolytic products are denoted by the arrowheads and th
markers (kDa) are indicated on the left.Higher MMP-9 expression has also been observed in many different
types of cancer [21–23] in which both microenvironment- [44,45]
and tumor-derivedMMP-9 [46] have been shown to inﬂuence tumor
cell invasion, metastasis [47,48], intravasation [49], and angiogenesis
[1,50].
One of the key mechanisms leading to activation of proteases, in
both normal and diseased conditions, is via proteolytic cascades
involving the activation of one protease leading to further activation
of proteases from same and other protease families. Such proteolytic
activation cascades are known to play an important role in processes
such as extracellular matrix degradation, which leads to tumor
invasion [51] and progression of many different neoplastic condi-
tions [52]. Most of the MMPs are secreted as latent zymogens and are
activated by the proteolytic removal of the propeptide domain [10].
Previous studies have shown that many proteases, such as trypsin
[53], plasmin [54,55], and chymase [56] as well as other MMPs (e.g.,
MMP-3 [57], MMP-7 [58]), can activate proMMP-9 in vitro.
KLK7, a chymotryptic-like serine protease, was initially puriﬁed
and characterized from human skin extracts and is thought to play a
role in desquamation of human skin [59,60], however, increasingly
the KLK7 transcript and/or KLK7 protein has been found to be
overexpressed in human cancers. Previously, we reported that KLK7 is
overexpressed in pancreatic adenocarcinomas [26]. Other laboratories
have also demonstrated that it is overexpressed in ovarian [29–31,61],
squamous cervical [28], and breast cancers [27]. Interestingly, inmany
of these cancers there is a parallel in the overexpression of KLK7 and
MMPs, such as MMP-9 and MMP-2 [62–64]. Based on these observa-
tions, we sought to determine whether KLK7 could activate proMMP-9
and proMMP-2.
Using a series of in vitro experimentswe found that KLK7was able to
cleave proMMP-9 to produce a novel truncated fragment with
gelatinolytic activity in a time-dependent manner. Activation of the
92-kDa proMMP-9 by other proteases typically yields an 83-kDa active
protease. Using a ﬁvefold molar excess of substrate (proMMP-9) to
enzyme (KLK7), KLK7-cleaved MMP-9 products exhibited robust
gelatinolytic activity that was clearly evident within 15 minutes and
the proMMP-9 was completely activated by 4 h. This rapid activation of
proMMP-9 by KLK7 is reminiscent of the activation reported forMMP-3
using similar reaction conditions [57] and appears much more efﬁcient
than activation by trypsin [53]. Furthermore, MMP-3 has been
demonstrated to generate an active 82-kDa form of MMP-9 that is
subsequently converted into a major gelatinase with a mass of 35 kDa(A)MDA-MB-231 conditionedmedium containing 50 mM EDTAwas incubated at 37 °C
nd thermolysin (lane 3), or with 1 pmol proMMP-9 and 0.2 pmol thermolysin-activated
lysin-activated KLK7 in SFM containing EDTA at 37 °C for 4 h (lane 5). At the end of the
oned medium was immunodepleted with a TIMP-1 antibody (B) or control goat IgG (C).
) at 37 °C for 4 h prior to analysis by gelatin zymography (upper panels) or western blot
pmol thermolysin-activated KLK7 in SFM containing EDTA at 37 °C for 4 h (lane 5). The
ermolysin-directed proteolysis (therm) is indicated by the arrow. Sizes of the protein
1530 V.C. Ramani et al. / Biochimica et Biophysica Acta 1813 (2011) 1525–1531[65]. Intriguingly, in a study using a transgenic mouse model of
pancreatic islet carcinogenesis, an unidentiﬁed 43-kDa gelatinolytic
activitywas observed during the angiogenic switch triggered byMMP-9
[66], similar in size to the novel gelatinolytic fragments observed in this
study. Although no direct conclusions can be made about the
involvement of KLK7 in the production of this low-molecular weight
gelatinolytic activity, the ability of KLK7 to produce similar gelatinolytic
activities from MMP-9 in vitro warrants further investigation into this
potential link.
In mixtures of gelatinases, the presence and activity MMP-9 and
MMP-2 is often based solely on the size of the proteolytic products
observed by gelatin zymography, with higher molecular weight
products assigned as MMP-9 and lower molecular weight products
designated as MMP-2. In view of the low-molecular weight
proteolytically active MMP-9 produced by KLK7, identiﬁcation of
these gelatinases should likely include additional methodologies.
To determine whether the activation of proMMP-9 by KLK7 was
speciﬁc to this gelatinase, we also tested the ability of KLK7 to activate
proMMP-2. In contrast to the vigorous activation of MMP-9, no
activation of proMMP-2 was observed upon incubation with KLK7
under similar reaction conditions. These results clearly show KLK7-
dependent activation is speciﬁc for MMP-9, which is similar to the
cleavage proﬁles observed for other proteolytic MMP activators.
MDA-MMP-9 cells have been used previously in studying
activators of MMP-9 [11]. The level of proMMP-9 is much higher
than TIMP-1 in these cells and they do not have detectable levels of
MMP-2 [11] or KLK7[38]; thus, this cell line provides a good cell-based
system to conﬁrm the activation of proMMP-9 by KLK7. When active
KLK7 was incubated with conditioned medium from these cells, a
truncated, active fragment was produced similar to that observed
using puriﬁed components. Interestingly, a second novel gelatinolytic
band was also detected. A similar pattern of active MMP-9 products
was also observedwhen puriﬁed proMMP-9was incubatedwith KLK7
in SFM. The rapid activation of MMP-9 by KLK7 in these experimental
settings suggests that KLK7 may play an important role in the
activation of MMP-9 in tissues, where both MMP-9 and KLK7 have
been reported to be overexpressed, such as pancreatic cancer.
To identify cellular factors that may regulate KLK7-activation of
MMP-9, we employed MDA-MB-231 cells, the parental cell line used
to generate the MMP-9-expressing cells. Incubation of proMMP-9 and
KLK7 in MDA-MB-231 conditioned medium failed to produce the
truncated active MMP-9 band and generated only very low levels of
the second truncated fragment, observed with MDA-MMP-9 condi-
tioned medium, suggesting the presence of an inhibitory factor. Since
TIMP-1 is known to inﬂuence both the activation and activity of MMP-
9, the MDA-MB-231 conditioned medium was immunodepleted
speciﬁcally for TIMP-1 and KLK7-dependent MMP-9 activation was
restored. The interaction of TIMP-1 with MMP-9 may prevent its
dimerization and activation. Thus, though KLK7 is a novel activator of
proMMP-9, the activation is attenuated by TIMP-1 similar to other
proteases, suggesting that the balance between proMMP-9 and TIMP-
1 cannot be circumvented by KLK7.
Interestingly, the possible link between activation of MMP-9 and a
chymotryptic-like protease has been previously reported. In human
skin, TNF-α-induced proteolytic activation of MMP-9 was found to be
mediated by a chymotryptic-like serine protease and controlled by
TIMP-1 [67]. Since KLK7 is a chymotrypsin-like protease predomi-
nantly expressed in human skin, it presents an intriguing possibility
that KLK7 is responsible for the MMP-9 activation observed in this
study.
We further used plasmin-activated KLK7 for testing KLK7-mediated
MMP-9 activation to ensure that EDTA included to inhibit thermolysin
did not alter the conformation of proMMP-9, thereby exposing sites that
are usually not accessible for proteolytic activation of MMP-9 under
physiological conditions. Additionally, plasmin activation of KLK7
clearly points out to the possibility of a novel proteolytic activationcascade (plasmin→KLK7→MMP-9) in pathological states where all
three proteases are expressed.
Though a clear role for the novel truncated MMP-9 we have
observed is not known, it is possible that in neoplastic conditions
these fragments could have possible pro-tumorigenic effects similar
to those ascribed to the 83-kDa form of MMP-9 produced through the
actions of other proteases. Most importantly this catalytically active
fragment also lacks the C-terminal hemopexin domain, which is
thought to mediate protein-protein interactions and contribute to
substrate speciﬁcity; thus, this truncated MMPmay engage additional
substrates not targeted by full-length MMP-9.
In conclusion, the results of this study clearly indicate that unique
low-molecular weight active MMP-9 fragments can be produced
through the proteolytic action of KLK7 and suggests a novel role of
KLK7 during its aberrant expression in human cancers, supporting the
notion that it may play a signiﬁcant part in tumor development and
progression. Our present study highlights the need for understanding
further the role of other protease families, like KLKs, in activating
MMPs and the importance of taking into consideration such
proteolytically active fragments while designing new therapies.
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